You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcetic acid
Accession NumberDB03166  (DB04184, EXPT00423)
TypeSmall Molecule
GroupsApproved
Description

Acetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.

Structure
Thumb
Synonyms
SynonymLanguageCode
ACETATE ionNot AvailableNot Available
Acetic acid, ion(1-)Not AvailableNot Available
AzetatNot AvailableNot Available
CH3-COO(-)Not AvailableNot Available
EthanoatNot AvailableNot Available
EthanoateNot AvailableNot Available
MeCO2 anionNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vosolsolution20.65 mg/mLauricular (otic)ECR Pharmaceuticals Co., Inc.2010-03-15Not AvailableUs
Acetic Acidirrigant.25 g/100mLirrigationB. Braun Medical Inc.1979-08-06Not AvailableUs
Acetic Acidirrigant250 mg/100mLirrigationBaxter Healthcare Corporation1982-02-19Not AvailableUs
Acetic Acidirrigant250 mg/100mLirrigationHospira, Inc.1980-01-01Not AvailableUs
Acetic Acidsolution20.65 mg/mLauricular (otic)Rebel Distributors Corp2010-01-22Not AvailableUs
Acetic Acidsolution20.65 mg/mLauricular (otic)Hi Tech Pharmacal Co., Inc.2010-01-22Not AvailableUs
Acetic Acidsolution20.65 mg/mLauricular (otic)A S Medication Solutions Llc2010-01-22Not AvailableUs
Acetic Acidsolution20.65 mg/mLauricular (otic)Dispensing Solutions, Inc.2010-01-22Not AvailableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acetic Acidsolution.02 mL/mLauricular (otic)Qualitest Pharmaceuticals2005-02-24Not AvailableUs
Borofairsolution/ drops2 mg/mLauricular (otic)Major Pharmaceuticals1994-02-25Not AvailableUs
Acetic Acidsolution/ drops2 mg/mLauricular (otic)Bausch & Lomb Incorporated1994-02-25Not AvailableUs
Acetic Acidsolution25 mg/mLauricular (otic)Morton Grove Pharmaceuticals, Inc.1996-07-26Not AvailableUs
Over the Counter ProductsNot Available
International Brands
NameCompany
AcetasolNot Available
VolsolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number64-19-7
WeightAverage: 59.044
Monoisotopic: 59.01330434
Chemical FormulaC2H3O2
InChI KeyQTBSBXVTEAMEQO-UHFFFAOYSA-M
InChI
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)/p-1
IUPAC Name
acetate
SMILES
CC([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acids
Direct ParentCarboxylic acids
Alternative Parents
Substituents
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Organic anion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat infections in the ear canal.
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Bacteria
Pathways
PathwayCategorySMPDB ID
Heroin Metabolism PathwayDrug metabolismSMP00623
Ethanol DegradationMetabolicSMP00449
Heroin Action PathwayDrug actionSMP00407
Tay-Sachs DiseaseDiseaseSMP00390
Sialuria or French Type SialuriaDiseaseSMP00217
Amino Sugar MetabolismMetabolicSMP00045
Sialuria or French Type SialuriaDiseaseSMP00216
G(M2)-Gangliosidosis: Variant B, Tay-sachs diseaseDiseaseSMP00534
Salla Disease/Infantile Sialic Acid Storage DiseaseDiseaseSMP00240
Fatty Acid BiosynthesisMetabolicSMP00456
Canavan DiseaseDiseaseSMP00175
HypoacetylaspartiaDiseaseSMP00192
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)DiseaseSMP00334
Primary hyperoxaluria II, PH2DiseaseSMP00558
Pyruvate MetabolismMetabolicSMP00060
Pyruvate Dehydrogenase Complex DeficiencyDiseaseSMP00212
Pyruvate kinase deficiencyDiseaseSMP00559
Aspartate MetabolismMetabolicSMP00067
Leigh SyndromeDiseaseSMP00196
Disulfiram Action PathwayDrug actionSMP00429
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9502
Blood Brain Barrier+0.9742
Caco-2 permeable+0.5968
P-glycoprotein substrateNon-substrate0.8714
P-glycoprotein inhibitor INon-inhibitor0.99
P-glycoprotein inhibitor IINon-inhibitor0.992
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.7913
CYP450 2D6 substrateNon-substrate0.9384
CYP450 3A4 substrateNon-substrate0.7921
CYP450 1A2 substrateNon-inhibitor0.8774
CYP450 2C9 substrateNon-inhibitor0.9482
CYP450 2D6 substrateNon-inhibitor0.9667
CYP450 2C19 substrateNon-inhibitor0.9786
CYP450 3A4 substrateNon-inhibitor0.9854
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9818
Ames testNon AMES toxic0.9635
CarcinogenicityCarcinogens 0.6222
BiodegradationReady biodegradable0.9758
Rat acute toxicity1.6315 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9666
hERG inhibition (predictor II)Non-inhibitor0.9889
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Irrigantirrigation.25 g/100mL
Irrigantirrigation250 mg/100mL
Solutionauricular (otic).02 mL/mL
Solutionauricular (otic)20.65 mg/mL
Solutionauricular (otic)25 mg/mL
Solution/ dropsauricular (otic)2 mg/mL
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point16.6 °CPhysProp
boiling point117.9 °CPhysProp
water solubility1E+006 mg/L (at 25 °C)MERCK INDEX (1996)
logP-0.17HANSCH,C ET AL. (1995)
logS1.22ADME Research, USCD
pKa4.76 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility490.0 mg/mLALOGPS
logP-0.29ALOGPS
logP-0.22ChemAxon
logS0.8ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Earl M. Chamberlin, Warren K. Russ, Jr., George G. Hazen, “Process for preparing [1-oxo-2-cyclopentyl (or 2-isopropyl)-2-methyl-6,7-dichloro-5-indanyloxy] acetic acid.” U.S. Patent US3950408, issued April, 1928.

US3950408
General Reference
  1. eMedicine
External Links
ATC CodesG01AD02S02AA10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Transporters

1. Solute carrier organic anion transporter family member 2B1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 2B1 O94956 Details

References:

  1. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. Pubmed
  2. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. Pubmed

2. Monocarboxylate transporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Monocarboxylate transporter 1 P53985 Details

References:

  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:20